Distribution of gram-negative bacteria in lower respiratory tract infections and their susceptibility patterns to beta-lactam antibiotics during the COVID-19 pandemic
,
Abstract
Background and Objectives: Inappropriate antibiotic use can lead to resistance, particularly in Gram-negative bacteria. The aimd of this study was to identify the distribution of Gram-negative bacteria responsible for lower respiratory tract infections and to assess their susceptibility profiles to beta-lactam antibiotics in the periods before and during the COVID-19 pandemic.
Materials and Methods: This retrospective cross-sectional study utilized secondary data from WHONET 2022, drawing on a database of Gram-negative bacteria isolated from lower respiratory tract specimens processed at the Clinical Microbiology Laboratory, Faculty of Medicine, Universitas Indonesia, during the period of 2018-2021. Susceptibility to ampicillin-sulbactam, ceftazidime, cefepime, meropenem, and piperacillin-tazobactam was assessed. Comparisons between the pre-pandemic and pandemic periods were conducted using the chi-square test.
Results: A total of 569 samples were analyzed, comprising 383 samples from the pre-pandemic period (2018-2019) and 186 samples from the COVID-19 pandemic period (2020-2021). Twenty-nine Gram-negative bacterial species were identified before the pandemic, compared with 19 species during the COVID-19 pandemic. Klebsiella pneumoniae emerged as the most common pathogen, with a prevalance of 30.29% before and 27.96% during the COVID-19 pandemic. Statistical analysis revealed significant differences in the resistance patterns of Acinetobacter baumannii to cefepime (p= 0.036), ceftazidime (p= 0.018), and piperacillin-tazobactam (p= 0.002). Conversely, no significant differences were observed for K. pneumoniae and Pseudomonas aeruginosa (p > 0.05).
Conclusion: K. Pneumoniae remains the predominant Gram-negative pathogen causing lower respiratory tract infections, whereas A. baumannii shows an increased disease burden and resistance during the COVID-19 pandemic. This underscores the importance of continuous surveillance of antimicrobial resistance.
2. Shi Y, Wang G, Cai XP, Deng JW, Zheng L, Zhu HH, et al. An overview of COVID-19. J Zhejiang Univ Sci B 2020; 21: 343-360.
3. Fazel P, Sedighian H, Behzadi E, Kachuei R, Imani Fooladi AA. Interaction between SARS-CoV-2 and pathogenic bacteria. Curr Microbiol 2023; 80: 223.
4. Wu G, Lu J, Liu D, He Y. Characteristics and risk factors of secondary bacterial infections in COVID-19 patients. Antimicrob Steward Healthc Epidemiol 2023; 3(1): e156.
5. Garcia-Bustos V, Cabañero-Navalón MD, Salavert Lletí M. Resistance to beta-lactams in Gram-negative bacilli: relevance and potential therapeutic alternatives. Rev Esp Quimioter 2022; 35(Suppl 2): 1-15.
6. Wulandari RA, Fauzia S, Kurniasari F. Investigations on the risk factors of Acute Respiratory Infections (ARIs) among under-five children in Depok City, Indonesia. Ann Ig 2024; 36: 15-25.
7. Sannathimmappa MB, Nambiar V, Aravindakshan R, Al-Kasaby NM. Profile and antibiotic-resistance pattern of bacteria isolated from endotracheal secretions of mechanically ventilated patients at a tertiary care hospital. J Educ Health Promot 2021; 10: 195.
8. Cleveland Clinic. Upper respiratory infection [Internet]. Cleveland (OH): Cleveland Clinic; 2021 [cited 2024 Oct 9]. Available from: https://my.clevelandclinic.org/health/articles/4022-upper-respiratory-infection
9. Oliveira J. Gram-negative bacteria [Internet]. U.S. National Library of Medicine; 2023 [cited 2025 Mar 11]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538213/.
10. Duan N, Du J, Huang C, Li H. Microbial distribution and antibiotic susceptibility of lower respiratory tract infections patients from pediatric ward, adult respiratory ward, and respiratory intensive care unit. Front Microbiol 2020; 11: 1480.
11. Centers for Disease Control and Prevention. About Pseudomonas aeruginosa disease [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; 2024 [cited 2024 Oct 9]. Available from: https://www.cdc.gov/pseudomonas-aeruginosa/about/index.html
12. Blakeborough L, Watson JS. The importance of obtaining a sputum sample and how it can aid diagnosis and treatment. Br J Nurs 2019; 28: 295-298.
13. Altamimi I, Binkhamis K, Alhumimidi A, Alabdulkarim IM, Almugren A, Alhemsi H, et al. Decline in ESBL Production and Carbapenem Resistance in Urinary Tract Infections among Key Bacterial Species during the COVID-19 Pandemic. Antibiotics (Basel) 2024; 13: 216.
14. Tanislav C, Kostev K. Fewer non-COVID-19 respiratory tract infections and gastrointestinal infections during the COVID-19 pandemic. J Med Virol 2021; 94: 298-302.
15. Santella B, Serretiello E, De Filippis A, Veronica F, Iervolino D, Dell'Annunziata F, et al. Lower Respiratory Tract Pathogens and Their Antimicrobial Susceptibility Pattern: A 5-Year Study. Antibiotics (Basel) 2021; 10: 851.
16. Maebed AZM, Gaber Y, Bakeer W, Dishisha T. Microbial etiologies of ventilator-associated pneumonia (VAP) in intensive care unit of Beni-Suef University's Hospital. Beni Suef Univ J Basic Appl Sci 2021; 10: 41.
17. Khadka S, Barakoti A, Adhikari RP, Khanal LK, Sapkota J. Positive Bacterial Culture among Lower Respiratory Tract Specimens of Patients in a Tertiary Care Center: A Descriptive Cross-sectional Study. JNMA J Nepal Med Assoc 2022; 60: 384-388.
18. Kumar A, Chakravorty S, Yang T, Russo TA, Newton SM, Klebba PE. Siderophore-mediated iron acquisition by Klebsiella pneumoniae. J Bacteriol 2024; 206(5): e0002424.
19. Jalali Y, Liptáková A, Jalali M, Payer J. Moving toward Extensively Drug-Resistant: Four-Year Antimicrobial Resistance Trends of Acinetobacter baumannii from the Largest Department of Internal Medicine in Slovakia. Antibiotics (Basel) 2023; 12: 1200.
20. Borcan AM, Rotaru E, Caravia LG, Filipescu MC, Simoiu M. Trends in Antimicrobial Resistance of Acinetobacter baumannii and Pseudomonas aeruginosa from Bloodstream Infections: An Eight-Year Study in a Romanian Tertiary Hospital. Pharmaceuticals (Basel) 2025; 18: 948.
21. Abdelaziz Abdolmoneim S, Mohamed Ghazy R, Anwar Sultan E, Hassaan MA, Anwar Mahgoub M. Antimicrobial resistance burden pre- and post-COVID-19 pandemic with mapping the multidrug resistance in Egypt: a comparative cross-sectional study. Sci Rep 2024; 14: 7176.
22. Ficik J, Andrezál M, Drahovská H, Böhmer M, Szemes T, Liptáková A, et al. Carbapenem-Resistant Klebsiella pneumoniae in COVID-19 Era-Challenges and Solutions. Antibiotics (Basel) 2023; 12: 1285.
23. Xia J, Lu L, Zhao KL, Zeng QL. Resistance Transition of Pseudomonas aeruginosa in SARS-CoV-2-Uninfected Hospitalized Patients in the Pandemic. Infect Drug Resist 2023; 16: 6717-6724.
24. Golli AL, Popa SG, Ghenea AE, Turcu FL. The Impact of the COVID-19 Pandemic on the Antibiotic Resistance of Gram-Negative Pathogens Causing Bloodstream Infections in an Intensive Care Unit. Biomedicines 2025; 13: 379.
25. Rahbe E, Watier L, Guillemot D, Glaser P, Opatowski L. Determinants of worldwide antibiotic resistance dynamics across drug-bacterium pairs: a multivariable spatial-temporal analysis using ATLAS. Lancet Planet Health 2023; 7(7): e547-e557.
26. Lai CC, Chen SY, Ko WC, Hsueh PR. Increased antimicrobial resistance during the COVID-19 pandemic: a systematic review and meta-analysis of hospital-acquired infections. Int J Antimicrob Agents 2021; 57: 106324.
| Files | ||
| Issue | Vol 18 No 5 (2026) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/ijm.v18i5.22863 | |
| Keywords | ||
| Gram-negative bacteria Beta-lactams Bacterial distribution Lower respiratory tract infections Susceptibility patterns | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
